AstraZeneca, a pharmaceutical company, agreed to acquire LaNova Medicines, a clinical-stage innovative drug research and development company. Financial terms were not disclosed. “LaNova Medicines has a strong focus on discovering and developing innovative medicines in the ADC and immuno-oncology fields. We’re excited to reach this agreement with AstraZeneca," Crystal Qin, LaNova Medicines Founder, Chair and CEO.